Imatinib (Gleevec) specifically is an oral chemo medication used for the treatment of cancer. It acts in order to stop the Bcr-Abl tyrosine kinase. This may slow the growth or result in the programmed cell death of certain sorts of cancerous cells.
In the late 1990s, Imatinib was originated by scientists at Ciba-Geigy (which merged with the Sandoz in the year of 1996 to become Novartis), in a team led by the biochemist named Nicholas Lydon and that included Jürg Zimmermann and Elisabeth Buchdunger.
In the year of 1998, Imatinib's first clinical trial took place, after Novartis reluctantly synthesized and released a few grams of the medication for Druker, enough for him in order to run a trial using a 100 or so patients.
In the month of May 2001, Imatinib received Food and Drug Administration approval, only 2 and a half years following the submission of a new drug application.
In the month of December, 2008, the Food and Drug Administration approved imatinib in order to prevent the recurrence of rare Gastrointestinal Cancer.
In the month of January, 2012, the Food and Drug Administration approved imatinib for the expanded use in patients with the rare Gastrointestinal Cancer.
In the month of January, 2013, the Food and Drug Application approved imatinib in order to treat children with the Acute Lymphoblastic Leukemia.
The imatinib price in India is around 1064 INR for a supply of strips of 10 tablets, depending on the wholesaler/pharmacy you visit and also brand you choose. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy Imatinib.
Comments